Zai Lab (NASDAQ:ZLAB) and Deciphera Pharmaceuticals (NASDAQ:DCPH) announce that the China National Medical Products Administration has accepted its NDA for ripretinib (brand name Qinlock) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
On June 11, 2019 Zai Lab in-licensed exclusive ripretinib rights from Deciphera.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.